Julio Valentin Nieves, MD
Interventional Cardiology · Manati, PRNPI 1952535346
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $23,250 of the $31,737 with a category attached, or 73.3%. Boston Scientific accounts for 84.7% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2021 at $10,948 and has fallen 91.1% since, to $973 in 2025.
Across 525 payments — averaging $60.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$27K
- Medtronic$2K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$739
- Abbott$649
- Teleflex LLC$249
- AstraZeneca$189
- plus $587 from 11 others
What the payments were for
- Speaking & faculty fees$23,25073%
- Travel & lodging$8123%
- Food & beverage$7,60124%
- Gifts$750%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 262 | $26,867 |
| Medtronic(2 entities) | 147 | $2,458 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 27 | $739 |
| Abbott | 53 | $649 |
| Teleflex LLC | 4 | $249 |
| AstraZeneca | 9 | $189 |
| Chiesi USA, Inc. | 5 | $144 |
| Terumo Medical Corporation | 2 | $89 |
| Bayer | 1 | $76 |
| Cordis US CORP. | 5 | $74 |
| BD | 3 | $69 |
| Abiomed | 2 | $37 |
| Biotronik Inc. | 1 | $24 |
| Boehringer Ingelheim | 1 | $21 |
| Novartis | 1 | $20 |
| Inari Medical, Inc. | 1 | $19 |
| Cardinal Health P.r. 120 Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPTICROSS$7,200
- ROTAPRO$4,449
- GENERAL VASCULAR ACCESS$3,200
- GUIDEZILLA$2,100
- GENERAL - THERAPIES$2,000
- WOLVERINE CORONARY CUTTING BALLOON$1,800
- SYNERGY$1,750
- SAMURAI$1,200
- Resolute$232
- ONYX FRONTIER$187
- CoreValve Evolut$132
- ARCTIC FRONT ADVANCE$116
- Micra$115
- ANGIOJET$101
- LifeVest$100
How this compares
$31,737 in reported general payments places this provider in the 70th percentile of 39 interventional cardiology providers in Puerto Rico.
See all interventional cardiology providers in Puerto Rico →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 53 | $53,342 |
| BrilintaTicagrelor | 35 | $19,950 |
| Candesartan-HydrochlorothiazidCandesartan/Hydrochlorothiazid | 15 | $3,071 |
| ClopidogrelClopidogrel Bisulfate | 166 | $1,576 |
| Atorvastatin Calcium | 104 | $1,415 |
| Metoprolol Succinate | 93 | $1,286 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 79 | $1,243 |
| Losartan Potassium | 87 | $1,064 |
| Carvedilol | 81 | $718 |
| Rosuvastatin Calcium | 38 | $529 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 31 | $498 |
| Spironolactone | 49 | $388 |
| Amlodipine Besylate | 69 | $324 |
| Nifedipine ErNifedipine | 13 | $250 |
| Hydralazine Hcl | 27 | $191 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBrilinta | $189 | $19,95035 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 39 interventional cardiology providers in Puerto Rico.
Other interventional cardiology in Manati
- Ricardo SantiagoManati$131K
- Valentin del Rio SantiagoManati$28K
- Nelson Espinell GonzalezManati$9K
- Abner Nieves TorresManati$8K
- Damian Grovas AbadSan Juan$498K
- Eric Carro JimenezSan Juan$416K
- Hector Martinez GonzalezMayaguez$261K
- Alejandro Lopez MasPonce$142K
- Edwin I Perez MarreroSan Juan$129K
- Pedro Colon HernandezCaguas$128K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.